Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek Ltd has informed BSE that the trading window for dealing in its securities will remain closed from Wednesday, October 1, 2025, until 48 hours after the declaration of limited reviewed financial results for the second quarter ended September 30, 2025. The closure applies to all Directors, Key Managerial Personnel, Designated Employees, and Connected Persons as defined under SEBI's Insider Trading Regulations, 2015. The company has stated that the date of the Board Meeting to consider and approve the unaudited Q2 financial results will be communicated separately in due course. The intimation has been signed by Dr. K. Koteswara Rao, Managing Director.
This is a routine SEBI compliance announcement indicating that Q2 FY26 results are imminent, typically within the next few weeks. Shareholders should watch for the upcoming board meeting date and earnings announcement, as quarterly results can be a material event for the stock.